Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sontra faces NASDAQ delisting:

This article was originally published in Clinica

Executive Summary

Transdermal drug delivery device developer Sontra Medical has fallen below the listing threshold for continued listing of its shares on NASDAQ, and must submit a plan of action to the market's authorities by December 7. The Franklin Lakes, Massachusetts-based developer of continuous glucose measurement technology, based on its SonoPrep skin permeation device, had shareholder equity of $1.65m in late September, below the $2.5m threshold prescribed by NASDAQ. Companies must meet this, or one of two other criteria, for continued listing: $500,000 net income in the latest year (or in two of three most recent financial years); or $35m market capitalisation. The company has already this year fallen below the $1 per share minimum bid price criterion.

You may also be interested in...



French OTC Industry Frustrated By Regulatory Clampdown in 2019

Speaking exclusively to HBW Insight, French OTC association Afipa reflects on a difficult 2019 which saw tighter restrictions introduced on the sale of popular consumer health products. The trade group believes the industry's best prospects for a brighter future are rebuilding relations with national drug regulator ANSM and to getting self-care higher up the agenda of the French government.

Will MDR Delays Create Roadblocks For Companion Diagnostics Regulation?

Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed is there a risk of delays to these products being able to demonstrate compliance?

India Rare Disease Policy Proposes Crowdfunding But Patients Feel Let Down

Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.

Topics

UsernamePublicRestriction

Register

MT053645

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel